Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Biomea Fusion, Inc. director Ray Sumita received a stock option grant covering 196,299 shares of common stock. The option has an exercise price of $1.1500 per share and expires on June 9, 2036. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, subject to Sumita’s continued service. Following this compensation-related award, Sumita holds 196,299 derivative securities directly, with no open-market buying or selling reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ray Sumita
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 196,299 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 196,299 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 196,299 options
Exercise price: $1.1500 per share
Underlying shares: 196,299 shares
+2 more
5 metrics
Options granted
196,299 options
Stock Option (Right to Buy) granted on June 10, 2026
Exercise price
$1.1500 per share
Conversion or exercise price of granted options
Underlying shares
196,299 shares
Underlying common stock for granted options
Expiration date
June 9, 2036
Option expiration for director grant
Derivative holdings after grant
196,299 options
Total derivative securities following transaction
Key Terms
Stock Option (Right to Buy), conversion or exercise price, expiration date, annual meeting of the Issuer's stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 1.1500"
expiration date financial
"expiration_date: 2036-06-09T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of the Issuer's stockholders financial
"immediately prior to the annual meeting of the Issuer's stockholders"
continued service financial
"subject to the Reporting Person's continued service to the Issuer"
FAQ
What did Biomea Fusion (BMEA) director Ray Sumita report in this Form 4?
Ray Sumita reported receiving a stock option grant for 196,299 shares of Biomea Fusion common stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed exercise price.
How many Biomea Fusion (BMEA) options were granted to Ray Sumita?
Ray Sumita was granted options on 196,299 shares of Biomea Fusion common stock. This entire amount represents new derivative securities, and his total derivative holdings after the transaction are 196,299 options held directly in his name.
What is the exercise price and expiration date of Ray Sumita’s BMEA stock options?
The granted stock options have an exercise price of $1.1500 per share and an expiration date of June 9, 2036. This means Sumita can choose to buy shares at that price any time before the expiration date, once vested.
When do Ray Sumita’s Biomea Fusion (BMEA) options vest?
The options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting. Vesting is conditioned on Ray Sumita’s continued service to Biomea Fusion through the applicable vesting date.
How many Biomea Fusion (BMEA) derivative securities does Ray Sumita hold after this grant?
Following this transaction, Ray Sumita holds 196,299 derivative securities, all from the new stock option grant. The Form 4 lists this figure as his total derivative holdings after the transaction, with ownership reported as direct.